ValuEngine upgraded shares of Recro Pharma (NASDAQ:REPH) from a hold rating to a buy rating in a report published on Tuesday morning.
Other research analysts have also issued research reports about the company. Oppenheimer set a $18.00 price target on Recro Pharma and gave the stock a buy rating in a research note on Wednesday, September 5th. Janney Montgomery Scott set a $13.00 price target on Recro Pharma and gave the stock a buy rating in a research note on Monday, October 1st. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $12.88.
Shares of Recro Pharma stock opened at $7.35 on Tuesday. Recro Pharma has a fifty-two week low of $4.78 and a fifty-two week high of $13.05. The firm has a market cap of $147.30 million, a price-to-earnings ratio of -3.69 and a beta of -0.51. The company has a debt-to-equity ratio of 2.22, a quick ratio of 1.42 and a current ratio of 1.59.
Recro Pharma (NASDAQ:REPH) last issued its quarterly earnings results on Wednesday, November 7th. The specialty pharmaceutical company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.03. Recro Pharma had a negative return on equity of 144.84% and a negative net margin of 75.19%. The company had revenue of $18.28 million for the quarter, compared to analyst estimates of $16.77 million. Analysts expect that Recro Pharma will post -2.46 earnings per share for the current fiscal year.
Several hedge funds have recently added to or reduced their stakes in REPH. Newtyn Management LLC acquired a new stake in shares of Recro Pharma during the 2nd quarter worth $4,456,000. Engine Capital Management LP increased its holdings in shares of Recro Pharma by 472.3% during the 2nd quarter. Engine Capital Management LP now owns 391,307 shares of the specialty pharmaceutical company’s stock worth $1,964,000 after buying an additional 322,937 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of Recro Pharma during the 1st quarter worth $3,060,000. Sanders Morris Harris LLC acquired a new stake in shares of Recro Pharma during the 2nd quarter worth $1,391,000. Finally, BlackRock Inc. increased its holdings in shares of Recro Pharma by 27.6% during the 2nd quarter. BlackRock Inc. now owns 1,144,988 shares of the specialty pharmaceutical company’s stock worth $5,747,000 after buying an additional 247,559 shares during the last quarter. Institutional investors and hedge funds own 54.79% of the company’s stock.
About Recro Pharma
Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Featured Article: How to invest in a bear market
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.